 Akcea Therapeutics, Inc. NASDAQ: AKCA, a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that AIFA, or The Italian Medicines Agency, has granted approval for the reimbursement of TEGSEDI inotersen for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin hATTR amyloidosis. 